Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Major ABO Incompatibility in Non-Myeloablative Hematopoietic Stem Cell Transplant for Sickle Cell Disease-Not an Insurmountable Obstacle.
Pediatr Blood Cancer
January 2025
Blood and Marrow Transplant/Cellular Therapy Program, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
With advances in conditioning strategies and graft-versus-host disease (GvHD) prevention, hematopoietic stem cell transplantation (HSCT) is a safe, curative treatment option for pediatric patients with sickle cell disease (SCD). However, donor options have been limited in non-myeloablative matched sibling donor (MSD) setting by excluding recipients with major ABO blood group incompatible donors due to concern of the risk of significant complications such as pure red cell aplasia (PRCA). We present three cases of successful HSCT with major ABO incompatibility with their donors, and discuss strategies to safely expand the donor pool to include these donors.
View Article and Find Full Text PDFA successful haploidentical transplantation without conditioning regimen for a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy.
Cytotherapy
December 2024
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. Electronic address:
Background Aims: With novel therapies improving prognosis, the complications of multiple myeloma after multi-line treatment, particularly myelosuppression, have become a crucial determinant of long-term outcomes. Non-myeloablative allogeneic hematopoietic stem cell transplantation is a feasible option, but the transplant-related mortality rate remains high. Our study presents a relapsed/refractory multiple myeloma patient with a 9-year disease history.
View Article and Find Full Text PDFLipid Levels Increase to the Normal Range After Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease.
Transplant Cell Ther
December 2024
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address:
Individuals with sickle cell disease (SCD) have a unique type of dyslipidemia characterized by low total cholesterol (TC), low low-density lipoprotein cholesterol (LDL-c), low high-density lipoprotein cholesterol (HDL-c), and normal triglycerides (TG). This lipid state is theorized to be cardioprotective against atherosclerosis. In SCD, hematopoietic cell transplant (HCT) offers a potentially curative therapy.
View Article and Find Full Text PDFEffect of ABO Mismatch and Red Blood Cell Alloimmunization on the Outcome of Hematopoietic Cell Transplantation for Sickle Cell Disease.
Transplant Cell Ther
January 2025
Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Ministry of National Guards-Health Affairs, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Saudi Scientific Society of Blood and Marrow Transplantation, Jeddah, Saudi Arabia. Electronic address:
Article Synopsis
- * ABO blood group mismatch and alloimmunization can significantly affect the success of HCT in SCD patients, leading to complications like hemolysis and graft failure.
- * This study analyzed data from 194 SCD patients over 14 years old who underwent HCT and focused on the effects of RBC incompatibility and alloimmunization on transplant outcomes and overall survival.
The current state of tolerance induction in vascularized composite allotransplantation.
Curr Opin Organ Transplant
December 2024
Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Colorado Denver/Anschutz Medical Campus, Aurora, Colorado, USA.
Purpose Of Review: Significant advancements have been made in the field of vascularized composite allotransplantation (VCA); however, like solid organ transplantation, bypassing the recipient's immune response remains a significant obstacle to long-term allograft survival. Therefore, strategies to overcome acute and chronic rejection and minimize immunosuppressive therapy are crucial for the future of VCA. This review highlights recent attempts to induce tolerance in VCA and discusses key findings through a clinical lens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!